20 June 2013
Keywords: globeimmune, tarmogen, plus, soc, shows, evr, 12-week
Article | 24 April 2009
12-week Phase II trial data show that patients treated with GI-5005, GlobeImmune's targeted molecular Tarmogen (immunogen) for hepatitis C
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
24 April 2009
27 April 2009
19 June 2013
© 2013 thepharmaletter.com